Medical technicians work at a drive-through coronavirus disease (COVID-19) test facility on the Regeneron Pharmaceuticals company’s Westchester campus in Tarrytown, New York, on September 17, 2020.
Brendan McDermid | Reuters
RegeneronThe share price rose over 4% on the Thursday before trading on the stock exchange when it filed an application for an Emergency Use Authorization (EUA) for the treatment of Covid-19 antibodies with the US Food and Drug Administration.
President Donald Trump performed monoclonal antibody coronavirus therapy “REGN-COV2” last week after the coronavirus was diagnosed. He has since then described it as a “cure”.
The biotech company published a statement Wednesday: “If an EUA is granted, the (US) government has committed itself to making these cans available to the American people free of charge and would be responsible for their distribution.”
Doses are currently available for approximately 50,000 patients, Regeneron said, “and we expect a total of doses to be available for 300,000 patients over the next several months.”
REGN-COV2 is a combination of two monoclonal antibodies and was “specially developed to block the infectivity” of the virus (SARS-CoV-2) that causes Covid-19.
Trump received an 8-gram dose of the antibody cocktail at the beginning of his Covid-19 infection, even though it was not approved by the FDA.
According to Regeneron, preclinical studies have shown that REGN-COV2 reduces the amount of virus and associated damage in the lungs of non-human primates. The company recently partnered with Roche Increase in the worldwide supply of REGN-COV2, if approved.
“If REGNCOV2 is shown to be safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the US (beyond initial delivery by the US government) and Roche will develop, manufacture and develop it outside of the US expel, “said the company.